{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"3.6","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Progression-Free Survival was defined as the duration from the date of registration until the date of disease progression per RECIST or death due to any cause. Patients known to be alive without evidence of disease progression were censored at the date of last contact. Disease progression was defined as a \\>= 20% increase over nadir in the sum of longest diameters of target lesions, unequivocal progression of non-target lesions in the opinion of the treating investigator, appearance of new lesions, symptomatic deterioration, or death due to disease","dispersionType":"95% Confidence Interval","groups":[{"description":"Daily oral Everolimus 10 mg/day\n\neverolimus","id":"OG000","title":"Everolimus"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression, up to 3 years.","title":"Progression-Free Survival","type":"PRIMARY","unitOfMeasure":"months"}